×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NASDAQ:KPTI

Karyopharm Therapeutics Stock Forecast, Price & News

$5.17
+0.04 (+0.78%)
(As of 06/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.86
$5.26
50-Day Range
$4.15
$7.80
52-Week Range
$4.02
$14.73
Volume
2.48 million shs
Average Volume
3.17 million shs
Market Capitalization
$410.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.57
30 days | 90 days | 365 days | Advanced Chart

Receive KPTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KPTI Stock Forecast (MarketRank)

Overall MarketRank

2.41 out of 5 stars

Medical Sector

188th out of 1,418 stocks

Pharmaceutical Preparations Industry

76th out of 679 stocks

Analyst Opinion: 3.2Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
Karyopharm Therapeutics logo

About Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

KPTI Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KPTI
Fax
N/A
Employees
442
Year Founded
N/A

Company Calendar

Last Earnings
5/05/2022
Today
6/24/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$11.57
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+123.8%
Consensus Rating
Hold
Rating Score (0-4)
2.33333333333333
Research Coverage
6 Analysts

Profitability

Net Income
$-124.09 million
Pretax Margin
-46.03%

Debt

Sales & Book Value

Annual Sales
$209.82 million
Book Value
($1.05) per share

Miscellaneous

Free Float
71,286,000
Market Cap
$410.59 million
Optionable
Optionable
Beta
-0.16














Karyopharm Therapeutics Frequently Asked Questions

Should I buy or sell Karyopharm Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Karyopharm Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KPTI, but not buy additional shares or sell existing shares.
View analyst ratings for Karyopharm Therapeutics
or view top-rated stocks.

What is Karyopharm Therapeutics' stock price forecast for 2022?

6 Wall Street research analysts have issued twelve-month price objectives for Karyopharm Therapeutics' stock. Their KPTI stock forecasts range from $6.00 to $22.00. On average, they anticipate Karyopharm Therapeutics' stock price to reach $11.57 in the next twelve months. This suggests a possible upside of 123.8% from the stock's current price.
View analysts' price targets for Karyopharm Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Karyopharm Therapeutics' stock performed in 2022?

Karyopharm Therapeutics' stock was trading at $6.43 at the beginning of the year. Since then, KPTI stock has decreased by 19.6% and is now trading at $5.17.
View the best growth stocks for 2022 here
.

When is Karyopharm Therapeutics' next earnings date?

Karyopharm Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Karyopharm Therapeutics
.

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced its quarterly earnings data on Thursday, May, 5th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.63) by $0.10. The firm had revenue of $47.67 million for the quarter, compared to analyst estimates of $34.78 million. During the same quarter last year, the company earned ($0.77) earnings per share.
View Karyopharm Therapeutics' earnings history
.

Who are Karyopharm Therapeutics' key executives?

Karyopharm Therapeutics' management team includes the following people:
  • Mr. Richard A. Paulson M.B.A., Pres, CEO & Director (Age 55, Pay $1.27M)
  • Dr. Sharon Shacham M.B.A., Ph.D., Co-Founder & Chairman of Scientific Advisory Board (Age 52, Pay $766.54k)
  • Mr. Michael P. Mason CPA, M.B.A., Exec. VP, CFO & Treasurer (Age 47, Pay $692.39k) (LinkedIn Profile)
  • Mr. Ran Frenkel R.Ph., RPh, Exec. VP & Chief Devel. Officer (Age 53, Pay $667.87k)
  • Dr. Mansoor Raza Mirza M.D., Clinical Consultant, Member of Scientific Advisory Board & Independent Director (Age 61, Pay $146.14k)
  • Mr. Cameron Peters, VP of Fin., Assistant Treasurer & Principal Accounting Officer (Age 62)
  • Mr. Pierre S. Sayad M.S., Ph.D., VP of Global Medical & Scientific Affairs
  • Ms. Elhan Webb C.F.A., Sr. VP of Investor Relations
  • Mr. Michael J. Mano J.D., Sr. VP, Gen. Counsel & Sec. (Age 45)
  • Ms. Lisa Meletta J.D., VP of Legal & Chief Compliance Officer

What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO?

31 employees have rated Karyopharm Therapeutics CEO Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among Karyopharm Therapeutics' employees.

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Who are Karyopharm Therapeutics' major shareholders?

Karyopharm Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (13.81%), BlackRock Inc. (9.98%), Palo Alto Investors LP (7.08%), Vanguard Group Inc. (4.99%), Rice Hall James & Associates LLC (1.69%) and Rice Hall James & Associates LLC (1.69%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Deepika Pakianathan, Garen G Bohlin, Jatin Shah, John Demaree, Mansoor Raza Mirza, Michael Kauffman, Michael Mason, Ran Frenkel, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener and Tanya Lewis.
View institutional ownership trends for Karyopharm Therapeutics
.

Which institutional investors are selling Karyopharm Therapeutics stock?

KPTI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Frontier Capital Management Co. LLC, Citigroup Inc., Group One Trading L.P., Simplex Trading LLC, Dupont Capital Management Corp, Allianz Asset Management GmbH, and Rhumbline Advisers. Company insiders that have sold Karyopharm Therapeutics company stock in the last two years include Christopher Brett Primiano, Deepika Pakianathan, Jatin Shah, Mansoor Raza Mirza, Michael Kauffman, Michael Mason, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener, and Tanya Lewis.
View insider buying and selling activity for Karyopharm Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Karyopharm Therapeutics stock?

KPTI stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Bank of America Corp DE, Vanguard Group Inc., Acadian Asset Management LLC, Candriam Luxembourg S.C.A., UBS Group AG, Victory Capital Management Inc., and Palo Alto Investors LP. Company insiders that have bought Karyopharm Therapeutics stock in the last two years include Garen G Bohlin, Jatin Shah, and John Demaree.
View insider buying and selling activity for Karyopharm Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Karyopharm Therapeutics' stock price today?

One share of KPTI stock can currently be purchased for approximately $5.17.

How much money does Karyopharm Therapeutics make?

Karyopharm Therapeutics (NASDAQ:KPTI) has a market capitalization of $410.59 million and generates $209.82 million in revenue each year. The company earns $-124.09 million in net income (profit) each year or ($1.470010) on an earnings per share basis.

How many employees does Karyopharm Therapeutics have?

Karyopharm Therapeutics employs 442 workers across the globe.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The official website for Karyopharm Therapeutics is www.karyopharm.com. The company can be reached via phone at (617) 658-0600 or via email at [email protected].

This page (NASDAQ:KPTI) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.